Onco Precision
Founded 2020 · 15 employees on LinkedIn · 4 known investors
Find your way into Onco Precision
3 people in our graph share verified history with the Onco Precision team — schools, employers, funds. One of them is your warm intro.
Felipe Ossiounlockedknows Gastón Soria · together at Onco Precision
×2knows the team · via Onco Precision
OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.
Founders & leadership
Onco Precision was founded in 2020 by Gastón Soria.
GS
Gastón SoriainCo-Founder & CSOGastón Soria is Co-Founder and Chief Scientific Officer of OncoPrecision, a precision oncology company developing antibody-drug conjugates and bispecific antibodies for blood cancers and hard-to-treat solid tumors. He spent nearly two decades in academia, with expertise in cell-based synthetic lethality systems for drug and target discovery.
Investors · 4
Competitors · 4
by search overlapOncosenx5 shared keywordsOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Oncusp Therapeutics4 shared keywordsOnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
Oncotelic Therapeutics3 shared keywordsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Onc3 shared keywordsOnc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making. Its products serve pharma companies with Phase IB/II clinical trial decisions and predict immunotherapy response and outcomes for metastatic lung cancer patients.
Companies competing with Onco Precision for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Onco Precision do?
- OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.
- Who founded Onco Precision?
- Onco Precision was founded by Gastón Soria in 2020.
- Who are Onco Precision's investors?
- Onco Precision's investors include AIR Capital, Creative Ventures, GRIDX, SOSV.